RA Capital Management is a Boston-based investment firm focused on healthcare, life sciences, and planetary health, investing in public and private companies across stages from seed to late-stage financings. The firm emphasizes evidence-based, science-led investing guided by internal research capabilities, including TechAtlas. It operates Raven, a biomedical innovation incubator that supports entrepreneurs and developers, and pursues value creation through collaborative partnerships, often co-investing and taking board positions. With a multidisciplinary, data-driven approach, RA Capital seeks to back management teams from inception through commercialization and beyond, aiming to improve patient outcomes and advance medical innovation.

OrbiMed is a global healthcare-focused investment firm founded in 1989 and headquartered in New York. It manages assets across public and private markets and pursues opportunities across the healthcare spectrum, including biopharmaceuticals, medical devices, diagnostics, digital health, and health services. The firm invests in startups, growth-stage companies, and established entities, leveraging scientific and medical expertise to support development and commercialization. It also offers financing solutions such as structured debt and royalty monetization for intellectual property and medical diagnostics.

Eli Lilly and Company is a global pharmaceutical company engaged in the discovery, development, manufacturing, and marketing of medicines for human health. It operates manufacturing facilities in the United States, Puerto Rico, and about 25 other countries, with products sold in approximately 135 countries. The company also conducts research in animal health, including efforts to improve disease treatments in animals and the efficiency of animal food production. Its therapeutic focus includes neuroscience, cardiometabolic diseases, cancer, and immunology, with a portfolio of medicines addressing conditions such as cancer, diabetes, autoimmune disorders, and neurodegenerative diseases. Eli Lilly and Company is committed to high standards of safety and quality in manufacturing and to expanding access to therapies through global operations and patient support initiatives.

Novo Nordisk is a global healthcare company focused on discovering, developing, and delivering medicines for serious chronic diseases, with a core emphasis on diabetes care. The organization produces and distributes insulin and other therapies aimed at treating diabetes and related conditions, while investing heavily in scientific research and biopharmaceutical innovation. Through partnerships and sustained commitments to accessibility, Novo Nordisk seeks to improve patient outcomes and support health systems worldwide. The company operates across many markets, supported by its production of insulin pens and a broad portfolio addressing obesity, rare blood and endocrine disorders, and other chronic diseases. It pursues long-term social responsibility and sustainability as integral to its business model.

Qiming Venture Partners is a China-based venture capital firm founded in 2006, with offices in Shanghai, Beijing, Suzhou, Hong Kong, and Singapore. It invests in technology, consumer, and healthcare companies at early and growth stages, providing hands-on support and strategic resources in addition to capital. The firm has backed hundreds of portfolio companies and has a record of exits through IPOs and M&A, including unicorn and super unicorn companies. It maintains an international presence through a U.S. team established in 2017, with offices in Cambridge, Seattle, and San Francisco to support healthcare and life sciences entrepreneurs and help portfolio companies scale globally. Qiming emphasizes sector knowledge, founder collaboration, and a long-term partnership approach to drive milestone achievements and create lasting value.

Founded in 1985, The Invus Group is a global private equity firm that partners with entrepreneurs, founders and management teams across the company lifecycle. Blending a family-office approach with multi-strategy investing, it supports transformative growth in sectors including consumer products and services, technology, life sciences, software, agtech, industrials, education and medical devices. The firm pursues long-term value creation through strategic insight, capital and execution, investing in companies from early stages to mature businesses and providing both lead investments and co-investments in private transactions worldwide. It maintains a global footprint with offices in New York, London, Paris and Hong Kong and has a flexible structure designed to align incentives with partners over time.

SOSV is a global venture capital firm that provides early-stage and seed investments alongside structured accelerator programs and deeply resourced facilities to accelerate product development. Focused on deep tech, human and planetary health, and cross-border software, SOSV backs startups from pre-seed onward and runs programs that accelerate technical development, regulatory strategy, and fundraising. The firm maintains labs and engineering spaces with specialist staff in multiple regions, including the United States and Asia, to support portfolio companies in biosafety, chemistry, mechatronics, analytics, and electrical engineering. Programs such as HAX and other live events offer founders access to prototyping, testing, and investor networks. Annually, SOSV makes around sixty pre-seed investments (up to roughly $550k each) and participates in numerous follow-on rounds, leveraging a global portfolio and extensive co-investor network to help deeply technical startups scale and reach markets.

Alexandria Venture Investments is the strategic venture capital arm of Alexandria Real Estate Equities. It provides seed through growth capital to life science and technology companies developing breakthrough therapies, diagnostics, research tools, agrifoodtech, agtech, digital health, and related platforms. Backed by the parent company’s industry experience and scientific advisory network, the firm leverages long-standing relationships and domain expertise to support early to growth-stage ventures aiming to translate scientific advances into practical healthcare and technology solutions.

ARCH Venture Partners is a Chicago-based venture capital firm founded in 1986 that concentrates on science-driven investments in life sciences, biotechnology, medical technologies, and related fields. The firm backs companies at multiple stages, often co-founded with scientists and entrepreneurs, aiming to translate academic research and national laboratory innovations into therapies, diagnostics, and other breakthrough technologies. ARCH emphasizes deep involvement, technical expertise, and a wide network to support founders from early development through later rounds, acting as a partner rather than a passive investor. With a focus on markets centered in the United States and North America, the firm frequently funds startups emerging from universities and research institutions and has built a track record of helping scientists bring innovations to market.

Samsara BioCapital is a Palo Alto, California-based biotechnology investment firm founded in 2016 that focuses on supporting transformative therapeutics. The firm seeks opportunities in the healthcare sector across the United States and invests in biotechnology companies with the potential to advance patient care. With a team drawn from scientific, medical, and business backgrounds, Samsara BioCapital aims to accelerate the development and commercialization of innovative drugs through strategic partnerships and hands-on collaboration. The approach emphasizes rigorous scientific evaluation and value creation for portfolio companies, helping entrepreneurs turn ideas into therapies with meaningful patient impact.

Venrock is a venture capital firm founded in 1969 as the venture capital arm of the Rockefeller family. It focuses on technology and healthcare, investing in seed and early-stage companies in the United States and pursuing life sciences and emerging technologies. The firm provides funding and strategic guidance to entrepreneurs with the aim of building enduring, high-growth companies. Its portfolio has included notable technology and biotech names such as Apple, Illumina, Gilead Sciences, and DoubleClick. Venrock maintains offices in Palo Alto, California, and New York, and emphasizes long-term partnerships with founders to accelerate innovation.

Vivo Capital is a global healthcare investment firm founded in 1996 and headquartered in Palo Alto, California, with offices in Asia. The firm manages approximately $5.8 billion in assets under management and has invested in over 290 public and private healthcare companies worldwide. Its multi‑fund platform covers growth equity, private equity including buyouts, venture capital, and public equity, and it makes investments across biotechnology, pharmaceuticals, medical devices, and healthcare services in major markets, with a focus on the United States and China. The team comprises about 50 professionals including physicians, scientists, entrepreneurs, operating executives, and industry experts who collaborate to build and grow high‑quality healthcare companies.

Morningside Group is a venture capital firm founded in 1986, originally established as a family office for the Chan family, and is based in the greater Boston area. The firm makes venture investments in companies with novel science and technology, pursuing a long-term, patient approach to company-building and emphasizing ethical practices. Its investment focus spans life sciences, digital health, artificial intelligence, materials science, and information technology. In addition to its investment activities, Morningside supports charitable initiatives in education, research, and healthcare, with partnerships including the Harvard T.H. Chan School of Public Health, UMass Chan Medical School, and the MIT Morningside Academy for Design.

New Enterprise Associates is a United States-based venture capital firm founded in 1977 and headquartered in Menlo Park, California. It invests in technology and healthcare companies across multiple stages, from seed to growth and IPO, and provides strategic support in product development and market expansion. The firm targets sectors including software, AI, consumer technology, digital health, life sciences, and energy technology, and pursues opportunities worldwide. NEA emphasizes long-term partnerships with founders, drawing on domain expertise and a broad network to help portfolio companies scale. It maintains a diverse portfolio across the United States, Asia and other regions, reflecting a global approach to venture investing.

Versant Ventures is a healthcare-focused venture capital firm founded in 1999 and headquartered in San Francisco. It invests across the healthcare sector, including life sciences, biotechnology, pharmaceuticals, and medical devices, at all stages with an emphasis on discovery and development of novel therapeutics. The firm operates globally with offices in Canada, the United States, and Europe, delivering hands-on support to portfolio companies through in-house scientific and operating expertise. Versant pursues collaborative partnerships with entrepreneurs to translate research into clinical and commercial success and has a track record of portfolio companies achieving successful acquisitions or IPOs. The firm is registered as an investment adviser.

Pfizer is a leading global biopharmaceutical company that discovers, develops, manufactures, and markets medicines and vaccines to address unmet medical needs. It maintains a broad portfolio across prescription medicines, vaccines, and treatments spanning internal medicine, inflammation and immunology, oncology, and other therapeutic areas, and it operates a sizable pipeline of investigational products with potential to address major diseases. The company conducts extensive global sales, with international markets contributing a substantial share of revenue, and it emphasizes scientific innovation, transparency, patient access, and ethical business practices. Its well-known products include Prevnar 13 and Eliquis, among others, and it continues to invest in research and development to advance new therapies. Based in the United States, Pfizer has a long history dating back to the 19th century and maintains a global footprint through manufacturing, partnerships, and philanthropic initiatives aimed at improving health outcomes worldwide.

Sofinnova Partners is an independent venture capital firm based in Paris, France, focusing on life sciences. It finances start-ups, early-stage companies, corporate spin-offs, and occasional turnarounds in biopharmaceuticals, biotech, medical devices, and related areas. The firm often acts as a lead or cornerstone investor and is frequently the first institutional backer in Series A rounds, maintaining an active role including board seats from formation through exit. It pursues global opportunities and emphasizes thorough due diligence on portfolio companies, including management and intellectual property considerations. The firm was established in 1972.

The European Innovation Council is a Brussels-based European Union organization established in 2018 to support deep‑tech innovation by helping startups, researchers and technology transfer activities move ideas toward market. It operates a portfolio of programs including Pathfinder, Accelerator, Transition, STEP Scale Up and Pre-Accelerator, and collaborates with partners to provide funding, mentorship and resources across the innovation lifecycle. The council emphasizes high-impact, science‑driven technologies with broad societal benefit and promotes inclusion, with initiatives to involve women‑led projects. It engages the wider ecosystem through awards, events and community initiatives and monitors impact through data platforms. By coordinating with private investors and other stakeholders, it aims to accelerate the scale-up of European deep‑tech firms and strengthen Europe’s position in global technology leadership.

Redmile Group is a San Francisco based investment firm specializing in healthcare, life sciences and related technology sectors. It pursues venture, growth, and crossover investments and provides strategic capital and operating experience to portfolio companies, supporting growth initiatives, acquisitions, and strategic partnerships. With offices in San Francisco and New York, the firm takes a hands-on approach, applying deep industry knowledge and networks to help portfolio companies scale and create long-term value for investors.

Mission BioCapital is a life sciences venture capital firm established in 2009 and based in Cambridge, Massachusetts, that funds early-stage biotechnology companies and supports them through clinical development. The firm emphasizes mentorship and practical assistance, offering entrepreneurs access to laboratory space, incubator networks, and programs designed to accelerate progress and secure follow-on funding. Its approach combines capital with hands-on guidance across discovery, development, and commercialization, leveraging a history of supporting dozens of startups. Through a broad ecosystem in the United States and Europe, Mission BioCapital aims to translate scientific discoveries into tangible solutions by pairing funding with operational support, expert advice in areas such as drug discovery, legal, and accounting, and strategic mentorship to help portfolio companies reach milestones and attract subsequent investment.

Forbion is a venture capital firm based in Naarden, Netherlands, with over twenty years of experience investing in biotech and life sciences. It focuses on human health, planetary health, and the bioeconomy, supporting early-stage and growth investments across Europe and North America in drug development, MedTech, and sustainable solutions. Its portfolio includes gene therapy and other innovative therapies for rare diseases. Forbion manages funds totaling about €5 billion in committed capital across multiple vehicles and prioritizes ESG principles in its investment approach, seeking to accelerate scientific advances and drive long-term value for portfolio companies.

Deerfield Management is a New York City–based healthcare investment and information platform that advances health outcomes through flexible funding, data-driven insights, and philanthropic support. The firm invests in and builds healthcare companies across biotechnology, pharmaceuticals, diagnostics, medical devices, healthcare services, and digital health, leveraging a dedicated research and development engine, Deerfield Discovery and Development, and in-house facilities that support scientific collaboration and discovery. Its Intelligence offering uses AI, data and market research to drive technology and strategy across its portfolio and the broader healthcare ecosystem. Deerfield operates the Cure hub housing portfolio companies and modern labs, and has partnered with organizations such as Blue Cross Blue Shield of North Carolina to develop services like Alo that assist independent physicians in managing the business of medicine. The Deerfield Foundation funds education, healthcare access and health outcomes initiatives, reflecting a broader philanthropic approach to accelerating medical innovation through partnerships and strategic collaborations.

Logos Capital is a San Francisco-based biotechnology investment firm founded in 2019 that combines in-house data analytics with scientific and clinical expertise to identify transformative therapies. The firm uses a disciplined, data-driven approach and a proprietary Logos Analytics platform to model clinical data, assess likelihood of clinical success, and support comprehensive underwriting, ongoing event tracking, and proactive risk management. Its team spans medical, scientific, and business disciplines, with the aim of delivering long-term returns through investments in therapies that have the potential to improve patient outcomes and redefine standards of care.

F-Prime Capital is a Cambridge, Massachusetts-based venture capital firm with a longstanding history of backing early- and growth-stage companies across life sciences and technology. The firm focuses on healthcare including therapeutics, medtech, and healthtech, as well as technology sectors such as enterprise software, fintech, frontier tech, and crypto ventures. Its team combines scientists, engineers, physicians, operators, and investors to provide hands-on support and strategic guidance designed to accelerate scalable growth. With a global footprint, F-Prime engages with portfolio companies across the Americas, Europe, and Asia, and maintains relationships with a wide network of industry experts to help startups advance from concept to market.

Deep Track Capital is a biotechnology investment firm based in Greenwich, Connecticut. It focuses on the life sciences and biotech sector, forging partnerships with management teams of innovative public and pre-IPO biotechnology companies, and aims to invest time, expertise, and its network alongside capital to support partners. The firm seeks to lead transactions while forming large syndicates and to participate in rounds led by other qualified investors.

Atlas Venture is a Cambridge, Massachusetts-based venture capital firm that specializes in building and funding early-stage biotechnology and life sciences companies, as well as technology ventures. Founded in 1980, it uses a seed-led venture creation approach to translate scientific discoveries into scalable medicines and biotech businesses, often acting as a lead investor and seeking board representation for portfolio companies.

SR One is the corporate venture capital arm of GlaxoSmithKline and a transatlantic biotechnology venture capital firm focused on translating innovative scientific discoveries into new medicines. It invests globally in life sciences companies pursuing breakthrough science that can significantly improve medical care, partnering with founders and entrepreneurs to move research from concept to therapy. The firm uses a back-and-build investment approach, prioritizing companies with strong fundamentals, clear development plans, and novel solutions to diseases, and it leverages its geographic reach on the West Coast of the United States and in London to provide strategic support and timely resources to portfolio companies. Since 1985, SR One has invested hundreds of millions of dollars in numerous companies, reflecting its role in bridging scientific innovation and medical progress.

TCG Crossover is a science-driven healthcare investment firm focused on identifying and advancing disruptive medicines. The firm invests in private and public biotechnology and health-technology companies led by entrepreneurs pursuing innovative treatments, with investment teams based in Palo Alto and New York City. Its approach emphasizes supporting ventures that aim to improve patient outcomes and accelerate pharmaceutical development through a research-driven portfolio and strategic backing.

Omega Funds is a Boston, Massachusetts-based venture capital firm focused on life sciences and healthcare investments across North America and Western Europe. The firm targets opportunities in the life sciences, digital health, immunology, rare diseases, precision medicine, oncology, cybersecurity, and software-as-a-service, leveraging an experienced team and broad network to support entrepreneurs and founders. It has facilitated the development of products reaching patients and has a track record that includes a public listing and an M&A deal. The firm operates across multiple funds and engages with the European ecosystem, sharing insights through publications such as the Omega Insights Series.

SV Health Investors is a private equity and venture capital firm that focuses on healthcare and life sciences, including biotech, therapeutics, and medtech. Founded in 1993 as SV Life Sciences, the firm operates globally with offices in Boston, San Francisco, and London and maintains a long US and Europe track record. It funds companies across stages, partnering with entrepreneurs to build breakthrough treatments and technologies, and provides strategic guidance and industry expertise to help portfolio companies grow and pursue IPOs or strategic transactions. With a team of over 50 professionals, SV Health Investors emphasizes value creation across its healthcare investments and seeks to transform healthcare through its portfolio.

Sofinnova Investments is a venture capital firm founded in 1976 and headquartered in Menlo Park, California, with offices in La Jolla, Montreal and Tokyo. It backs life sciences and information technology companies across the United States and Europe, from seed through early and growth stages. In life sciences, it targets clinical-stage pharmaceutical and biotechnology companies, drug discovery platforms, and medical technology addressing diseases with unmet medical needs, including oncology, respiratory, dermatology, ophthalmology, neurology and women's health. In information technology, it supports product-oriented software, enterprise IT solutions and telecommunications infrastructure. The firm often requires board participation for early-stage lead or co-lead investments and emphasizes hands-on guidance to help entrepreneurs build global businesses.

Kurma Partners is a Paris-based European investment firm that finances innovation in healthcare and biotechnology. It backs companies across development stages, from early research to expansion, with a focus on therapeutic solutions, diagnostics, healthtech and medtech, as well as digital health. Operating across Europe, it collaborates with research institutes, hospitals and seasoned entrepreneurs to translate scientific advances into clinical and commercial products. The company invests in life sciences, pharmaceuticals and related technologies, emphasizing sustainable and responsible investing and close collaboration with research centers and entrepreneurs to accelerate breakthroughs in healthcare and create long-term value.

Casdin Capital is a New York-based investment firm focused on the life sciences and healthcare sectors. It targets biotechnology, genomics, precision medicine, oncology, digital health, and related technologies, applying data-driven, research-intensive analysis to identify disruptive opportunities in the field. The firm makes private investments across stages and seeks to partner with companies developing innovative therapies, diagnostics, and tools that advance healthcare. Founded in 2012 by Eli Casdin, Casdin Capital operates as a registered investment adviser and emphasizes a long-term, fundamental approach to identifying paradigm shifts in life sciences.

Boxer Capital is a biotechnology investment firm that invests in private and public companies across the full drug development lifecycle, from early discovery to late-stage clinical and commercial programs. Based in the United States, it operates as part of the Tavistock Group and concentrates on biotechnology, life sciences, and precision and specialized medicine. The firm emphasizes disciplined, science-driven analysis and a multidisciplinary approach, with bottom-up idea generation supported by experienced scientists, aiming to advance innovative targets and therapies that improve patient care. It pursues opportunistic venture investments across private and public markets.

EcoR1 Capital is a San Francisco-based investment firm focused on the biotechnology sector. It partners with entrepreneurs to fund and accelerate the development of novel therapeutics, translating scientific insight into strategic value for portfolio companies and aiming to bring life-saving medicines to patients. The firm seeks long-term collaborations across biology and chemistry to capture breakthroughs at the molecular level and expand the drug discovery toolkit.

The Column Group is a San Francisco-based venture capital firm focused on biotechnology and life sciences, including oncology and drug discovery. It supports startups from early discovery through commercialization, taking a long-term view to build companies around robust scientific platforms and multiple product opportunities rather than short-term exits. The firm emphasizes deep scientific expertise, strong teams, collaboration, and mentorship, exemplified by the Swanson Fellowship. It manages more than $4 billion in assets and has backed about 55 biotech companies, generating substantial returns and multiple exits. The organization operates a portfolio of funds to support its activities from discovery to market and maintains an edge-to-edge, long-term investment approach.

BioVenture, established in September 2013, specializes in early-stage venture capital investments in the field of life sciences, focusing on biotechnology, drug discovery, medical devices, and healthcare services companies. With a fund size of 540 million yuan, BioVenture provides capital and post-investment support to innovative companies with high growth potential. Backed by Suzhou Industrial Park and BioBay, BioVenture aims to become one of China's most successful medical and pharmaceutical venture funds by leveraging its industry expertise and resources. The team at BioVenture consists of senior investment professionals with deep knowledge of domestic and foreign markets, aiming to help companies grow rapidly and achieve greater success while delivering considerable returns to fund investors. Through joint venture development cooperation, BioVenture seeks to drive innovation and growth in the medical and pharmaceutical industry.

Nextech Invest is a Zurich-based investment firm that targets early-stage healthcare and life sciences companies globally. It focuses on precision medicine and oncology, supporting ventures developing cancer therapies, diagnostics, and related technologies. The firm emphasizes scientific validation and value creation, provides targeted funding and strategic guidance, and seeks board positions in its portfolio companies. Active across Europe and beyond, it pursues interdisciplinary projects that blend biology, medicine and technology to accelerate development from discovery to market.

Takeda Pharmaceutical is a global biopharmaceutical leader and Japan’s largest pharmaceutical company. It researches, develops, manufactures, and markets prescription medicines and vaccines across oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies. The company serves patients worldwide with a diversified geographic footprint—roughly half of revenue from the United States, about 10% from Japan, 25% from Europe, and 15% from Canada. Takeda emphasizes patient-centered growth, sustainability, and ethical practices, supported by a strong focus on research and development to translate science into transformative medicines.

HBM Healthcare Investments is a Swiss investment firm founded in 2001 that focuses on delivering access to a globally diversified portfolio of healthcare companies. Headquartered in Switzerland, the firm targets opportunities across human medicine, biotechnology, medical technology and diagnostics, investing in both private and public companies with established or near-market products. It emphasizes active portfolio management and provides strategic guidance to portfolio companies to support value creation. By leveraging demographic trends and medical innovation, the firm seeks attractive returns while maintaining a diversified asset mix that includes private holdings, public equities and funds. The company is noted for an attractive dividend policy with a yield around five percent.

High-Tech Gründerfonds is a Germany-based venture capital firm established in 2005 that funds early-stage technology startups in Germany. Based in Bonn with an office in Berlin, it supports companies across software, information technology, digital and industrial tech, life sciences, chemistry, IoT, energy, and related fields by providing initial capital and subsequent funding, complemented by active guidance from investment managers. The firm typically acts as a lead investor and cooperates with other investors to help portfolio companies advance from concept to market, with a focus on startups that have begun commercial operations. By combining financing with hands-on support, HTGF aims to help high-potential founders develop their technology, validate products, and scale within the German market.

IP Group is a global investment company that backs science- and technology-based ventures by commercialising intellectual property generated at research-intensive institutions. It manages the entire process from identifying suitable IP to developing companies or forming commercial partnerships, leveraging deep industry and financial insight to accelerate value creation for portfolio companies, partners, and investors. The firm concentrates on healthtech, deeptech, and cleantech sectors, providing capital, strategic guidance, and operational support to help translate scientific innovations into scalable businesses. IP Group collaborates with universities, superannuation funds, and corporations to build world-class companies and deploy capital across early-stage and growth opportunities. Notable initiatives include the Climate Catalyst Fund, launched with CEFC to scale decarbonisation technologies, reflecting a track record of pursuing sustainable impact alongside financial return.

5AM Ventures is a San Francisco-based venture capital firm that makes seed- and early-stage investments in life sciences, healthcare, and related technology companies. The firm backs biopharmaceuticals, medical technology, and research instrument businesses and maintains a separate office in Boston. Founded in 2002 by John Diekman and Andrew Schwab, it concentrates on U.S. opportunities in healthcare and life sciences and pursues partnerships with academics and entrepreneurs to support discovery and development of breakthrough science.

Khosla Ventures is a California-based venture capital firm founded in 2004 that provides capital and strategic support to technology-driven startups across early- to late-stage cycles. It pursues opportunities in AI, digital health, healthcare technologies, sustainability, fintech, consumer and enterprise technology, and other frontier areas, focusing on innovative business models and world-class teams. The firm emphasizes a contrarian, long-term approach and seeks to help entrepreneurs address meaningful societal and economic challenges through science, technology, and design.

VenBio Partners is a California-based venture capital firm with offices in San Francisco and Seattle, focused on life sciences and investing across the development spectrum in the United States. The firm aims to lead most of its investments and actively builds syndicates and teams to support portfolio companies. It emphasizes positions that enable potential acquisition partners, prioritizing strong intellectual property, CMC capabilities, and clearly defined clinical development plans, including trial design, endpoints, powering, and regulatory considerations. VenBio provides strategic guidance throughout development to maximize impact and foster long-term relationships with leaders in the field.

Hercules Capital is a specialty finance company that provides venture debt and senior secured loans to venture capital-backed companies across technology and life sciences. It focuses on structured debt and growth capital, offering financing options such as working capital facilities, equipment loans, and other debt instruments to high-growth, expansion-stage firms, complementing equity rounds and allowing companies to extend runways while preserving ownership. The firm primarily invests in United States-based companies across software, hardware, semiconductors, healthcare, and related sectors, including energy technology and information services. Exits are pursued through initial public offerings, private sales, mergers or acquisitions, or other liquidity events. Known for sector expertise and a broad capital base, it emphasizes flexible, customized financing solutions that align with a portfolio company's milestones and capital structure needs.

Third Rock Ventures is a Boston-based venture capital firm focused on building and funding life sciences companies. It invests in early-stage and growth-stage biotechnology, pharmaceuticals, medical devices, diagnostics, therapeutics, and health IT ventures. The firm provides substantial initial capital and seeks active involvement in portfolio companies, including leadership roles when appropriate, complemented by strategic collaborations to accelerate development. With offices in Boston and San Francisco, Third Rock supports American life science companies from inception through commercialization, emphasizing bold ideas that advance patient outcomes.

Canaan Partners is a global early-stage venture capital firm founded in 1987 and headquartered in San Francisco. It focuses on supporting technology and healthcare startups at the seed and early stages, investing across sectors such as fintech, enterprise software and cloud, marketplaces, frontier technologies, biopharma, digital health and medtech. The firm maintains an international footprint with offices in Israel and India and backs entrepreneurs by leveraging a broad network of strategic partners, customers and follow-on investors to help transform innovative ideas into global companies.

MPM Capital is a Cambridge-headquartered healthcare investment firm that funds biotechnology, oncology, and life sciences companies. It invests across the company lifecycle, from seed and early development to growth and late-stage programs, aiming to translate scientific advances into clinical outcomes. The firm backs ventures in medical technology, oncology, specialty pharma, and medical devices and pursues global opportunities in the United States, Europe, and Asia, with a focus on India. Founded in 1996, MPM Capital collaborates with researchers, clinicians, and entrepreneurs to support portfolio companies through development milestones and proof-of-concept data.

Pontifax Venture Capital is a Herzliya, Israel-based venture capital firm that specializes in healthcare and life sciences. The firm invests across the development spectrum, from early-stage startups to growth-stage clinical companies, with a focus on pharmaceutical, biotechnology, medical devices, diagnostics, and related healthcare technologies. It seeks disruptive ideas typically sourced from research centers and provides active, hands-on support, including strategic guidance, networking, and experience in M&A to help portfolio companies scale. While headquartered in Israel, Pontifax invests globally and maintains a presence that reflects broad access to innovation in life sciences. Since its founding in 2004, Pontifax has built a diversified portfolio of companies across life sciences and healthcare technology.